Patent Grant
12023036
The left atrial appendage (LAA) is a small organ attached to the left atrium of the heart as a pouch-like extension. In patients suffering from atrial fibrillation, the left atrial appendage may not properly contract with the left atrium, causing stagnant blood to pool within its interior, which can lead to the undesirable formation of thrombi within the left atrial appendage. Thrombi forming in the left atrial appendage may break loose from this area and enter the blood stream. Thrombi that migrate through the blood vessels may eventually plug a smaller vessel downstream and thereby contribute to stroke or heart attack. Clinical studies have shown that the majority of blood clots in patients with atrial fibrillation are found in the left atrial appendage. As a treatment, medical devices have been developed which are positioned in the left atrial appendage and deployed to close off the ostium of the left atrial appendage. Over time, the exposed surface(s) spanning the ostium of the left atrial appendage becomes covered with tissue (a process called endothelization), effectively removing the left atrial appendage from the circulatory system and reducing or eliminating the number of thrombi which may enter the blood stream from the left atrial appendage. A continuing need exists for improved medical devices and methods to monitor and control thrombus formation within the left atrial appendage of patients suffering from atrial fibrillation.
An example occlusive implant includes an expandable framework configured to shift between a collapsed configuration and an expanded configuration, an occlusive member disposed along at least a portion of the expandable framework and a first collar attached to the expandable framework. The occlusive implant also includes a sensor housing coupled to the first collar, the sensor housing having a first end and a second end opposite the first end and a second collar slidably disposed along an outer surface of the sensor housing. Further, the second collar is coupled to the expandable framework via a spring. The occlusive implant also includes a sensor disposed along the second end of the sensor housing.
In addition or alternatively, wherein elongation of the spring is configured to shift the second collar from a first position in which the second collar is adjacent the first collar to a second position in which the second collar is adjacent the sensor.
In addition or alternatively wherein the spring is wrapped around the outer surface of the sensor housing.
In addition or alternatively, wherein the spring includes a first end coupled to the first collar and a second end coupled to the second collar.
In addition or alternatively, wherein the spring includes a first end coupled to the sensor housing and a second end coupled to the second collar.
In addition or alternatively, wherein the first collar includes an aperture, and wherein the sensor housing extends within the aperture of the first collar.
In addition or alternatively, wherein the first collar extends circumferentially around an outer surface of the sensor housing.
In addition or alternatively, wherein the first collar and the expandable framework are formed from a monolithic sheet of material.
In addition or alternatively, wherein the expandable framework further includes a plurality of struts attached to the first collar.
In addition or alternatively, wherein the expandable framework further includes a plurality of struts attached to the sensor housing.
In addition or alternatively, wherein the first collar is configured to remain stationary relative to the sensor housing while the expandable framework shifts between the collapsed configuration and the expanded configuration.
In addition or alternatively, wherein the first collar is configured to remain stationary relative to the sensor housing while the second collar shifts along the outer surface of the sensor housing.
In addition or alternatively, wherein the sensor is positioned within the expandable framework such that the sensor faces away from the occlusive member.
In addition or alternatively, wherein a first portion of the occlusive member is attached to the expandable framework and a second portion of the occlusive member is attached to the second collar.
Another example occlusive implant includes an expandable framework configured to shift between a collapsed configuration and an expanded configuration, the expandable framework including a plurality of struts spaced around a longitudinal axis of the expandable framework. The occlusive implant also includes an occlusive member disposed along at least a portion of the expandable framework and a first collar attached to the plurality of struts of the expandable framework, the first collar defining an aperture, where a central region of the aperture is aligned with the longitudinal axis of the expandable framework. The occlusive collar also includes a sensor housing coupled to the first collar and extending along the longitudinal axis of the expandable framework, the sensor housing having a first end and a second end opposite the first end. The occlusive implant also includes a second collar slidably disposed along an outer surface of the sensor housing, wherein the second collar is coupled to the expandable framework via a spring. Further, the occlusive implant includes a sensor disposed along the second end of the sensor housing.
In addition or alternatively, wherein elongation of the spring is configured to shift the second collar from a first position in which the second collar is adjacent the first collar to a second position in which the second collar is adjacent the sensor.
In addition or alternatively, wherein the spring is wrapped around the outer surface of the sensor housing.
In addition or alternatively, wherein the spring includes a first end coupled to the first collar and a second end coupled to the second collar.
In addition or alternatively, wherein the first collar is configured to remain stationary relative to the sensor housing while the second collar shifts along the outer surface of the sensor housing.
An example method for occluding a left atrial appendage includes advancing an occlusive implant to the left atrial appendage, the occlusive implant including an expandable framework configured to shift between a collapsed configuration and an expanded configuration. The occlusive implant also includes an occlusive member disposed along at least a portion of the expandable framework and a first collar attached to the expandable framework. The occlusive implant also includes a sensor housing coupled to the first collar, the sensor housing having a first end and a second end opposite the first end. The occlusive implant also includes a second collar slidably disposed along an outer surface of the sensor housing, wherein the second collar is coupled to the expandable framework via a spring. The occlusive implant also includes a sensor disposed along the second end of the sensor housing. The method also includes expanding the expandable framework within the left atrial appendage.
The above summary of some embodiments, aspects, and/or examples is not intended to describe each embodiment or every implementation of the present disclosure. The figures and the detailed description which follows more particularly exemplify these embodiments.
The disclosure may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying drawings, in which:
While aspects of the disclosure are amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.
The following description should be read with reference to the drawings, which are not necessarily to scale, wherein like reference numerals indicate like elements throughout the several views. The detailed description and drawings are intended to illustrate but not limit the claimed disclosure. Those skilled in the art will recognize that the various elements described and/or shown may be arranged in various combinations and configurations without departing from the scope of the disclosure. The detailed description and drawings illustrate example embodiments of the claimed disclosure. However, in the interest of clarity and ease of understanding, while every feature and/or element may not be shown in each drawing, the feature(s) and/or element(s) may be understood to be present regardless, unless otherwise specified.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about”, in the context of numeric values, generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In many instances, the term “about” may include numbers that are rounded to the nearest significant figure. Other uses of the term “about” (e.g., in a context other than numeric values) may be assumed to have their ordinary and customary definition(s), as understood from and consistent with the context of the specification, unless otherwise specified. The recitation of numerical ranges by endpoints includes all numbers within that range, including the endpoints (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
Although some suitable dimensions, ranges, and/or values pertaining to various components, features and/or specifications are disclosed, one of skill in the art, incited by the present disclosure, would understand desired dimensions, ranges, and/or values may deviate from those expressly disclosed.
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. It is to be noted that in order to facilitate understanding, certain features of the disclosure may be described in the singular, even though those features may be plural or recurring within the disclosed embodiment(s). Each instance of the features may include and/or be encompassed by the singular disclosure(s), unless expressly stated to the contrary. For simplicity and clarity purposes, not all elements of the disclosure are necessarily shown in each figure or discussed in detail below. However, it will be understood that the following discussion may apply equally to any and/or all of the components for which there are more than one, unless explicitly stated to the contrary. Additionally, not all instances of some elements or features may be shown in each figure for clarity.
Relative terms such as “proximal”, “distal”, “advance”, “retract”, variants thereof, and the like, may be generally considered with respect to the positioning, direction, and/or operation of various elements relative to a user/operator/manipulator of the device, wherein “proximal” and “retract” indicate or refer to closer to or toward the user and “distal” and “advance” indicate or refer to farther from or away from the user. In some instances, the terms “proximal” and “distal” may be arbitrarily assigned in an effort to facilitate understanding of the disclosure, and such instances will be readily apparent to the skilled artisan. Other relative terms, such as “upstream”, “downstream”, “inflow”, and “outflow” refer to a direction of fluid flow within a lumen, such as a body lumen, a blood vessel, or within a device.
The term “extent” may be understood to mean a greatest measurement of a stated or identified dimension, unless the extent or dimension in question is preceded by or identified as a “minimum”, which may be understood to mean a smallest measurement of the stated or identified dimension. For example, “outer extent” may be understood to mean a maximum outer dimension, “radial extent” may be understood to mean a maximum radial dimension, “longitudinal extent” may be understood to mean a maximum longitudinal dimension, etc. Each instance of an “extent” may be different (e.g., axial, longitudinal, lateral, radial, circumferential, etc.) and will be apparent to the skilled person from the context of the individual usage. Generally, an “extent” may be considered a greatest possible dimension measured according to the intended usage, while a “minimum extent” may be considered a smallest possible dimension measured according to the intended usage. In some instances, an “extent” may generally be measured orthogonally within a plane and/or cross-section, but may be, as will be apparent from the particular context, measured differently—such as, but not limited to, angularly, radially, circumferentially (e.g., along an arc), etc.
The terms “monolithic” and “unitary” shall generally refer to an element or elements made from or consisting of a single structure or base unit/element. A monolithic and/or unitary element shall exclude structure and/or features made by assembling or otherwise joining multiple discrete elements together.
It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment(s) described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one skilled in the art to affect the particular feature, structure, or characteristic in connection with other embodiments, whether or not explicitly described, unless clearly stated to the contrary. That is, the various individual elements described below, even if not explicitly shown in a particular combination, are nevertheless contemplated as being combinable or arrangeable with each other to form other additional embodiments or to complement and/or enrich the described embodiment(s), as would be understood by one of ordinary skill in the art.
For the purpose of clarity, certain identifying numerical nomenclature (e.g., first, second, third, fourth, etc.) may be used throughout the description and/or claims to name and/or differentiate between various described and/or claimed features. It is to be understood that the numerical nomenclature is not intended to be limiting and is exemplary only. In some embodiments, alterations of and deviations from previously-used numerical nomenclature may be made in the interest of brevity and clarity. That is, a feature identified as a “first” element may later be referred to as a “second” element, a “third” element, etc. or may be omitted entirely, and/or a different feature may be referred to as the “first” element. The meaning and/or designation in each instance will be apparent to the skilled practitioner.
The occurrence of thrombi in the left atrial appendage (LAA) during atrial fibrillation may be due to stagnancy of blood pooling in the LAA. The pooled blood may still be pulled out of the left atrium by the left ventricle, however less effectively due to the irregular contraction of the left atrium caused by atrial fibrillation. Therefore, instead of an active support of the blood flow by a contracting left atrium and left atrial appendage, filling of the left ventricle may depend primarily or solely on the suction effect created by the left ventricle. However, the contraction of the left atrial appendage may not be in sync with the cycle of the left ventricle. For example, contraction of the left atrial appendage may be out of phase up to 180 degrees with the left ventricle, which may create significant resistance to the desired flow of blood. Further still, most left atrial appendage geometries are complex and highly variable, with large irregular surface areas and a narrow ostium or opening compared to the depth of the left atrial appendage. These aspects as well as others, taken individually or in various combinations, may lead to high flow resistance of blood out of the left atrial appendage.
In an effort to reduce the occurrence of thrombi formation within the left atrial appendage and prevent thrombi from entering the blood stream from within the left atrial appendage, it may be desirable to develop medical devices and/or occlusive implants that close off the left atrial appendage from the heart and/or circulatory system, thereby lowering the risk of stroke due to thrombolytic material entering the blood stream from the left atrial appendage. Additionally, in some instances it may be desirable to develop medical devices and/or occlusive implants that provide diagnostic functionality to the implantable medical device. For example, it may be desirable to design the medical device to include a sensor which may sense a variety of diagnostic information such as left atrial pressure, temperature, oxygen levels or the like. Example medical devices and/or occlusive implants designed to seal the left atrial appendage (or other similar openings) while also having diagnostic sensing capabilities are disclosed herein.
In some embodiments, the occlusive member 14 may be permeable or impermeable to blood and/or other fluids, such as water. In some embodiments, the occlusive member 14 may include a woven, braided and/or knitted material, a fiber, a sheet-like material, a fabric, a polymeric membrane, a metallic or polymeric mesh, a porous filter-like material, or other suitable construction. In some embodiments, the occlusive member 14 may prevent thrombi (i.e. blood clots, etc.) from passing through the occlusive member 14 and out of the left atrial appendage into the blood stream. In some embodiments, the occlusive member 14 may promote endothelialization after implantation, thereby effectively removing the left atrial appendage from the patient's circulatory system. Some suitable, but non-limiting, examples of materials for the occlusive member 14 are discussed below.
In some examples, the expandable framework 12, the plurality of anchor members 16 and/or other members/components of the expandable framework 12 disclosed herein may be integrally formed and/or cut from a unitary (e.g., monolithic) member. In some embodiments, the expandable framework 12 and the plurality of anchor members 16 may be integrally formed and/or cut from a unitary tubular member and subsequently formed and/or heat set to a desired shape in the expanded configuration. In some embodiments, the expandable framework 12 and the plurality of anchor members 16 may be integrally formed and/or cut from a unitary flat member, and then rolled or formed into a tubular structure and subsequently formed and/or heat set to the desired shape in the expanded configuration. Some exemplary means and/or methods of making and/or forming the expandable framework 12 include laser cutting, machining, punching, stamping, electro discharge machining (EDM), chemical dissolution, etc. Other means and/or methods are also contemplated.
As illustrated in
In some examples, the collar 34 may include a cylindrical metallic ring (e.g., a metallic collar) which is designed to permit the sensor housing 26 to extend therethrough. In some examples, the collar 34 may be fully or partially embedded in the sensor housing 26. For example, the sensor housing 26 may be over-molded over top of the collar 34. However, it is contemplated that the collar 34 may be fixedly attached to the sensor housing 26 via a variety of different attachment techniques. For example, the collar 34 may be attached to the sensor housing 26 using one or more of a screw thread, bayonet attachment, crimping, welding, press fitting, c-clips, a retaining ring, a snap fit, adhesives, gluing, soldering or any other suitable attachment technique.
The collar 34 may be constructed of a variety of materials. For example, the collar 34 may be formed from a metal, metal alloy, a polymer, a ceramic or any combinations thereof. Further, in some instances, the collar 34 may be constructed from the same material as the frame 12. For example, the frame 12 (including the struts 15) and the collar and 34 may be a monolithic structure whereby the frame 12, struts 15 and the collar 34 may be formed from the same monolithic base material. However, it can be appreciated that, in some examples, the frame 12 and the collar 34 may constructed as separate components, whereby the struts 15 of the frame 12 may be affixed to the collar 34.
A discussed above, the collar 34 may be designed to include a centralized aperture (e.g., opening) designed to permit the sensor housing 26 to extend therethrough. It can be appreciated that the centralized aperture of the collar 34 may include an inner diameter. It can be further appreciated that the sensor housing 26 may include an outer diameter which is sized to fit within the inner diameter of the collar 34.
It can be appreciated that, in some examples, the collar 34 may include one or more fixation components designed to allow the occlusive member 14 to attach thereto. For example, the collar 34 may include hooks, holes, tines, etc. designed to allow the occlusive member 14 to attach thereto. A discussed above, in some examples, the occlusive member 14 may constructed from a fabric, and therefore, may able to hook onto one or more of the hooks, holes, tines, etc. located on the collar 34.
The sensor housing 26 may be formed from a variety of materials. For example, the sensor housing may be formed from a glass, acrylic, polymer, metal, metal alloy, a ceramic or any combinations thereof. Additionally, the sensor housing 26 (including the sensor 30) may be formed from a biocompatible material.
The delivery system 20 may include a hub member 22 coupled to a proximal region of the delivery catheter 24. The hub member 22 may be manipulated by a clinician to direct the distal end region of the delivery catheter 24 to a position adjacent the left atrial appendage 50. In some embodiments, an occlusive implant delivery system may include a core wire 18. Further, a proximal end of the expandable framework 12 may be configured to releasably attach, join, couple, engage, or otherwise connect to the distal end of the core wire 18. In some embodiments, an end region of the expandable framework 12 may include a threaded insert coupled thereto. In some embodiments, the threaded insert may be configured to and/or adapted to couple with, join to, mate with, or otherwise engage a threaded member disposed at the distal end of a core wire 18. Other means of releasably coupling and/or engaging the proximal end of the expandable framework 12 to the distal end of the core wire 18 are also contemplated.
It can be appreciated that, in some instances, the core wire 18 (or any other component of the delivery system 20) may be releasably attached to the sensor housing 26. For example, in some instances, the core wire 18 may be releasably attached, engaged, joined, coupled, or otherwise connected to the sensor housing 26, the expandable framework 12, or any other component of the medical device 10 via a variety of different connection methods. For example, it is contemplated that the sensor housing 26 may include a threaded component configured to and/or adapted to couple with, join to, mate with, or otherwise engage a threaded member disposed at the distal end of a core wire 18.
Additionally,
Further, it can be appreciated that the elements of the expandable framework 12 may be tailored to increase the flexibility and compliance of the expandable framework 12 and/or the occlusive implant 10, thereby permitting the expandable framework 12 and/or the occlusive implant 10 to conform to the tissue around it, rather than forcing the tissue to conform to the expandable framework 12 and/or the occlusive implant 10. Additionally, in some instances, it may be desirable to design the occlusive implant 10 discussed above to include various features, components and/or configurations which improve the sealing capabilities of the occlusive implant 10 within the left atrial appendage. Several example occlusion devices including various sealing features are disclosed below.
As described above,
The detailed view of
The detailed view of
The detailed view of
The detailed view of
Additionally, while the sensor housing 326 has been described as including the attachment members 342, it is further contemplated that the attachment members 342 may be positioned and/or included on any portion of the expandable framework 312. For example, a core wire (not shown in
As shown in
It can be appreciated that, in some examples, after a delivery system is utilized to delivery and deploy the occlusive member 310 in the ostium of a left atrial appendage, the delivery system may be disengaged from the occlusive implant and removed from the body. Further, after removal of the delivery system, it may be desirable to cover the attachment members 342. In other words, in order to limit the attachment members 342 from potentially causing adverse effects such as device related thrombosis, it may be desirable to cover the attachment members 342 after positioning the occlusive member 310 in the ostium of the left atrial appendage. Collectively,
However, it is also contemplated that the occlusive member 310 shown in
Additionally,
It can be appreciated that a variety of mechanisms may be designed to “release” the second collar 344 after delivery and deployment of the occlusive member in the body. In some examples, the second collar 344 may automatically release and move proximally toward the sensor 330 with the deployment of the occlusive member from the delivery system. In other words, in some examples, the second collar 344 would release as soon as the occlusive implant was deployed out of the delivery catheter 24 (not shown in
The second housing member 554 may further include a sensor 530 disposed along the second end 529 of the second housing member 554 of the sensor housing 526. For example, the sensor 530 may include a variety of different types of sensors. For example, the sensor 530 may include a pressure sensor, a temperature sensor, an oxygen sensor, or the like. Additionally, it can be appreciated that the sensor 530 (and components defining the sensor 530) may be integrated into the second sensor housing 554 of the sensor housing 526. In some instances, the sensor 530 (and components thereof) may be fixedly attached to the end of the second housing member 554 (corresponding to the second end 529 of the sensor housing 526). For example, the sensor 530 may be fully or partially embedded into the material used to construct the second housing member 554 of the sensor housing 526.
In some instances, the collar 534 may be fixedly attached to the first housing member 552 using a variety of attachment techniques. For example, the collar 534 may be weld, swaged, crimped, glued, press-fit, over-molded, threaded, etc. to the first housing member 552. Additionally,
While not shown in
The materials that can be used for the various components of the occlusive implant 10 (and variations, systems or components thereof disclosed herein) and the various elements thereof disclosed herein may include those commonly associated with medical devices. For simplicity purposes, the following discussion refers to the occlusive implant 10 (and variations, systems or components disclosed herein). However, this is not intended to limit the devices and methods described herein, as the discussion may be applied to other elements, members, components, or devices disclosed herein.
In some embodiments, the occlusive implant 10 (and variations, systems or components thereof disclosed herein) may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material. Some examples of suitable metals and metal alloys include stainless steel, such as 444V, 444L, and 314LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R44035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R44003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; platinum; palladium; gold; combinations thereof; and the like; or any other suitable material.
As alluded to herein, within the family of commercially available nickel-titanium or nitinol alloys, is a category designated “linear elastic” or “non-super-elastic” which, although may be similar in chemistry to conventional shape memory and super elastic varieties, may exhibit distinct and useful mechanical properties. Linear elastic and/or non-super-elastic nitinol may be distinguished from super elastic nitinol in that the linear elastic and/or non-super-elastic nitinol does not display a substantial “superelastic plateau” or “flag region” in its stress/strain curve like super elastic nitinol does. Instead, in the linear elastic and/or non-super-elastic nitinol, as recoverable strain increases, the stress continues to increase in a substantially linear, or a somewhat, but not necessarily entirely linear relationship until plastic deformation begins or at least in a relationship that is more linear than the super elastic plateau and/or flag region that may be seen with super elastic nitinol. Thus, for the purposes of this disclosure linear elastic and/or non-super-elastic nitinol may also be termed “substantially” linear elastic and/or non-super-elastic nitinol.
In some cases, linear elastic and/or non-super-elastic nitinol may also be distinguishable from super elastic nitinol in that linear elastic and/or non-super-elastic nitinol may accept up to about 2-5% strain while remaining substantially elastic (e.g., before plastically deforming) whereas super elastic nitinol may accept up to about 8% strain before plastically deforming. Both of these materials can be distinguished from other linear elastic materials such as stainless steel (that can also be distinguished based on its composition), which may accept only about 0.2 to 0.44 percent strain before plastically deforming.
In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy is an alloy that does not show any martensite/austenite phase changes that are detectable by differential scanning calorimetry (DSC) and dynamic metal thermal analysis (DMTA) analysis over a large temperature range. For example, in some embodiments, there may be no martensite/austenite phase changes detectable by DSC and DMTA analysis in the range of about −60 degrees Celsius (° C.) to about 120° C. in the linear elastic and/or non-super-elastic nickel-titanium alloy. The mechanical bending properties of such material may therefore be generally inert to the effect of temperature over this very broad range of temperature. In some embodiments, the mechanical bending properties of the linear elastic and/or non-super-elastic nickel-titanium alloy at ambient or room temperature are substantially the same as the mechanical properties at body temperature, for example, in that they do not display a super-elastic plateau and/or flag region. In other words, across a broad temperature range, the linear elastic and/or non-super-elastic nickel-titanium alloy maintains its linear elastic and/or non-super-elastic characteristics and/or properties.
In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy may be in the range of about 50 to about 60 weight percent nickel, with the remainder being essentially titanium. In some embodiments, the composition is in the range of about 54 to about 57 weight percent nickel. One example of a suitable nickel-titanium alloy is FHP-NT alloy commercially available from Furukawa Techno Material Co. of Kanagawa, Japan. Other suitable materials may include ULTANIUM™ (available from Neo-Metrics) and GUM METAL™ (available from Toyota). In some other embodiments, a superelastic alloy, for example a superelastic nitinol can be used to achieve desired properties.
In at least some embodiments, portions or all of the occlusive implant 10 (and variations, systems or components thereof disclosed herein) may also be doped with, made of, or otherwise include a radiopaque material. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids a user in determining the location of the occlusive implant 10 (and variations, systems or components thereof disclosed herein). Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like. Additionally, other radiopaque marker bands and/or coils may also be incorporated into the design of the occlusive implant 10 (and variations, systems or components thereof disclosed herein) to achieve the same result.
In some embodiments, a degree of Magnetic Resonance Imaging (MM) compatibility is imparted into the occlusive implant 10 (and variations, systems or components thereof disclosed herein). For example, the occlusive implant 10 (and variations, systems or components thereof disclosed herein) and/or components or portions thereof, may be made of a material that does not substantially distort the image and create substantial artifacts (e.g., gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an MRI image. The occlusive implant 10 (and variations, systems or components disclosed herein) or portions thereof, may also be made from a material that the MRI machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R44003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R44035 such as MP35-N® and the like), nitinol, and the like, and others.
In some embodiments, the occlusive implant 10 (and variations, systems or components thereof disclosed herein) and/or portions thereof, may be made from or include a polymer or other suitable material. Some examples of suitable polymers may include copolymers, polyisobutylene-polyurethane, polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), Marlex high-density polyethylene, Marlex low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, ionomers, polyurethane silicone copolymers (for example, ElastEon® from Aortech Biomaterials or ChronoSil® from AdvanSource Biomaterials), biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments, the sheath can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6 percent LCP.
In some embodiments, the occlusive implant 10 (and variations, systems or components thereof disclosed herein) may include a textile material. Some examples of suitable textile materials may include synthetic yarns that may be flat, shaped, twisted, textured, pre-shrunk or un-shrunk. Synthetic biocompatible yarns suitable for use in the present disclosure include, but are not limited to, polyesters, including polyethylene terephthalate (PET) polyesters, polypropylenes, polyethylenes, polyurethanes, polyolefins, polyvinyls, polymethylacetates, polyamides, naphthalene dicarboxylene derivatives, natural silk, and polytetrafluoroethylenes. Moreover, at least one of the synthetic yarns may be a metallic yarn or a glass or ceramic yarn or fiber. Useful metallic yarns include those yarns made from or containing stainless steel, platinum, gold, titanium, tantalum or a Ni—Co—Cr-based alloy. The yarns may further include carbon, glass or ceramic fibers. Desirably, the yarns are made from thermoplastic materials including, but not limited to, polyesters, polypropylenes, polyethylenes, polyurethanes, polynaphthalenes, polytetrafluoroethylenes, and the like. The yarns may be of the multifilament, monofilament, or spun-types. The type and denier of the yarn chosen may be selected in a manner which forms a biocompatible and implantable prosthesis and, more particularly, a vascular structure having desirable properties.
In some embodiments, the occlusive implant 10 (and variations, systems or components thereof disclosed herein) may include and/or be treated with a suitable therapeutic agent. Some examples of suitable therapeutic agents may include anti-thrombogenic agents (such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone)); anti-proliferative agents (such as enoxaparin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid); anti-inflammatory agents (such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine); antineoplastic/antiproliferative/anti-mitotic agents (such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors); anesthetic agents (such as lidocaine, bupivacaine, and ropivacaine); anti-coagulants (such as D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, anti-thrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors, and tick antiplatelet peptides); vascular cell growth promoters (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters); vascular cell growth inhibitors (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin); cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vascoactive mechanisms.
While the discussion above is generally directed toward an occlusive implant for use in the left atrial appendage of the heart, the aforementioned features may also be useful in other types of medical implants where a fabric or membrane is attached to a frame or support structure including, but not limited to, implants for the treatment of aneurysms (e.g., abdominal aortic aneurysms, thoracic aortic aneurysms, etc.), replacement valve implants (e.g., replacement heart valve implants, replacement aortic valve implants, replacement mitral valve implants, replacement vascular valve implants, etc.), and/or other types of occlusive devices (e.g., atrial septal occluders, cerebral aneurysm occluders, peripheral artery occluders, etc.). Other useful applications of the disclosed features are also contemplated.
It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the disclosure. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments. The disclosure's scope is, of course, defined in the language in which the appended claims are expressed.
This application claims the benefit of priority of U.S. Provisional Application No. 63/127,573 filed Dec. 18, 2020, the entire disclosure of which is hereby incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1782830 | French | Jun 1876 | A |
| 1967318 | Monahan | Oct 1931 | A |
| 3402710 | Paleschuck | Sep 1968 | A |
| 3540431 | Mobin-Uddin | Nov 1970 | A |
| 3638652 | Kelley | Feb 1972 | A |
| 3844302 | Klein | Oct 1974 | A |
| 3874388 | King | Apr 1975 | A |
| 4007743 | Blake | Feb 1977 | A |
| 4309776 | Berguer | Jan 1982 | A |
| 4341218 | U | Jul 1982 | A |
| 4364392 | Strother et al. | Dec 1982 | A |
| 4545367 | Tucci | Oct 1985 | A |
| 4585000 | Hershenson | Apr 1986 | A |
| 4603693 | Conta et al. | Aug 1986 | A |
| 4611594 | Grayhack et al. | Sep 1986 | A |
| 4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
| 4638803 | Rand | Jan 1987 | A |
| 4665906 | Jervis | May 1987 | A |
| 4681588 | Ketharanathan | Jul 1987 | A |
| 4710192 | Liotta et al. | Dec 1987 | A |
| 4793348 | Palmaz | Dec 1988 | A |
| 4832055 | Palestrant | May 1989 | A |
| 4917089 | Sideris | Apr 1990 | A |
| 4921484 | Hillstead | May 1990 | A |
| 5037810 | Saliba, Jr. | Aug 1991 | A |
| 5041090 | Scheglov et al. | Aug 1991 | A |
| 5041093 | Chu | Aug 1991 | A |
| 5042707 | Taheri | Aug 1991 | A |
| 5053009 | Herzberg | Oct 1991 | A |
| 5064435 | Porter | Nov 1991 | A |
| 5071407 | Termin et al. | Dec 1991 | A |
| 5078736 | Behl | Jan 1992 | A |
| 5098440 | Hillstead | Mar 1992 | A |
| 5108420 | Marks | Apr 1992 | A |
| 5116360 | Pinchuk et al. | May 1992 | A |
| 5122136 | Guglielmi et al. | Jun 1992 | A |
| 5171259 | Inoue | Dec 1992 | A |
| 5176692 | Wilk et al. | Jan 1993 | A |
| 5192301 | Kamiya et al. | Mar 1993 | A |
| 5234458 | Metais | Aug 1993 | A |
| 5256146 | Ensminger et al. | Oct 1993 | A |
| 5258000 | Gianturco | Nov 1993 | A |
| 5258042 | Mehta | Nov 1993 | A |
| 5284488 | Sideris | Feb 1994 | A |
| 5304184 | Hathaway et al. | Apr 1994 | A |
| 5306234 | Johnson | Apr 1994 | A |
| 5334217 | Das | Aug 1994 | A |
| 5350398 | Pavcnik et al. | Sep 1994 | A |
| 5350399 | Erlebacher et al. | Sep 1994 | A |
| 5353784 | Nady-Mohamed | Oct 1994 | A |
| 5366460 | Eberbach | Nov 1994 | A |
| 5366504 | Andersen et al. | Nov 1994 | A |
| 5370657 | Irie | Dec 1994 | A |
| 5375612 | Cottenceau et al. | Dec 1994 | A |
| 5397355 | Marin et al. | Mar 1995 | A |
| 5409444 | Kensey et al. | Apr 1995 | A |
| 5417699 | Klein et al. | May 1995 | A |
| 5421832 | Lefebvre | Jun 1995 | A |
| 5425744 | Fagan et al. | Jun 1995 | A |
| 5433727 | Sideris | Jul 1995 | A |
| 5443454 | Tanabe et al. | Aug 1995 | A |
| 5443478 | Purdy | Aug 1995 | A |
| 5451235 | Lock et al. | Sep 1995 | A |
| 5464408 | Duc | Nov 1995 | A |
| 5469867 | Schmitt | Nov 1995 | A |
| 5490856 | Person et al. | Feb 1996 | A |
| 5522790 | Moll et al. | Jun 1996 | A |
| 5522822 | Phelps et al. | Jun 1996 | A |
| 5522836 | Palermo | Jun 1996 | A |
| 5527322 | Klein et al. | Jun 1996 | A |
| 5527338 | Purdy | Jun 1996 | A |
| 5569204 | Cramer | Oct 1996 | A |
| 5591196 | Marin et al. | Jan 1997 | A |
| 5614204 | Cochrum | Mar 1997 | A |
| 5634936 | Linden et al. | Jun 1997 | A |
| 5634942 | Chevillon et al. | Jun 1997 | A |
| 5637097 | Yoon | Jun 1997 | A |
| 5643282 | Kieturakis | Jul 1997 | A |
| 5643292 | Hart | Jul 1997 | A |
| 5649953 | Lefebvre | Jul 1997 | A |
| 5653690 | Booth et al. | Aug 1997 | A |
| 5662671 | Barbut et al. | Sep 1997 | A |
| 5669933 | Simon et al. | Sep 1997 | A |
| 5681347 | Cathcart et al. | Oct 1997 | A |
| 5690671 | McGurk et al. | Nov 1997 | A |
| 5693067 | Purdy | Dec 1997 | A |
| 5695525 | Mulhauser et al. | Dec 1997 | A |
| 5700285 | Myers et al. | Dec 1997 | A |
| 5702421 | Schneidt | Dec 1997 | A |
| 5709224 | Behl et al. | Jan 1998 | A |
| 5709704 | Nott et al. | Jan 1998 | A |
| 5709707 | Lock et al. | Jan 1998 | A |
| 5725552 | Kotula et al. | Mar 1998 | A |
| 5725568 | Hastings | Mar 1998 | A |
| 5733294 | Forber et al. | Mar 1998 | A |
| 5733302 | Myler et al. | Mar 1998 | A |
| 5735290 | Sterman et al. | Apr 1998 | A |
| 5749883 | Halperin | May 1998 | A |
| 5749894 | Engelson | May 1998 | A |
| 5766219 | Horton | Jun 1998 | A |
| 5769816 | Barbut et al. | Jun 1998 | A |
| 5776097 | Massoud | Jul 1998 | A |
| 5782860 | Epstein et al. | Jul 1998 | A |
| 5785679 | Abolfathi et al. | Jul 1998 | A |
| 5800457 | Gelbfish | Sep 1998 | A |
| 5800512 | Lentz et al. | Sep 1998 | A |
| 5810874 | Lefebrve | Sep 1998 | A |
| 5823198 | Jones et al. | Oct 1998 | A |
| 5830228 | Knapp et al. | Nov 1998 | A |
| 5836913 | Orth et al. | Nov 1998 | A |
| 5836968 | Simon et al. | Nov 1998 | A |
| 5843118 | Sepetka et al. | Dec 1998 | A |
| 5846260 | Maahs | Dec 1998 | A |
| 5846261 | Kotula et al. | Dec 1998 | A |
| 5849005 | Garrison | Dec 1998 | A |
| 5851232 | Lois | Dec 1998 | A |
| 5853422 | Huebsch et al. | Dec 1998 | A |
| 5855597 | Jayaraman | Jan 1999 | A |
| 5865802 | Yoon et al. | Jan 1999 | A |
| 5865791 | Whayne et al. | Feb 1999 | A |
| 5868708 | Hart et al. | Feb 1999 | A |
| 5876367 | Kaganov et al. | Mar 1999 | A |
| 5879366 | Shaw et al. | Mar 1999 | A |
| 5882340 | Yoon | Mar 1999 | A |
| 5885258 | Sachdeva et al. | Mar 1999 | A |
| 5891558 | Bell et al. | Apr 1999 | A |
| 5895399 | Barbut et al. | Apr 1999 | A |
| 5904680 | Kordis et al. | May 1999 | A |
| 5904703 | Gilson | May 1999 | A |
| 5906207 | Shen | May 1999 | A |
| 5910154 | Tsugita et al. | Jun 1999 | A |
| 5911734 | Tsugita et al. | Jun 1999 | A |
| 5916236 | Muijs Van de Moer et al. | Jun 1999 | A |
| 5928192 | Maahs | Jul 1999 | A |
| 5928260 | Chin et al. | Jul 1999 | A |
| 5935145 | Villar et al. | Aug 1999 | A |
| 5935147 | Kensey et al. | Aug 1999 | A |
| 5935148 | Villar et al. | Aug 1999 | A |
| 5941249 | Maynard | Aug 1999 | A |
| 5944738 | Amplatz et al. | Aug 1999 | A |
| 5947997 | Pavcnik et al. | Sep 1999 | A |
| 5951589 | Epstein et al. | Sep 1999 | A |
| 5951599 | McCrory | Sep 1999 | A |
| 5954694 | Sunseri | Sep 1999 | A |
| 5957940 | Tanner et al. | Sep 1999 | A |
| 5961545 | Lentz et al. | Oct 1999 | A |
| 5976174 | Ruiz | Nov 1999 | A |
| 5980514 | Kupiecki et al. | Nov 1999 | A |
| 5980555 | Barbut et al. | Nov 1999 | A |
| 5989281 | Barbut et al. | Nov 1999 | A |
| 5993469 | McKenzie et al. | Nov 1999 | A |
| 5993483 | Gianotti | Nov 1999 | A |
| 5997557 | Barbut et al. | Dec 1999 | A |
| 6004348 | Banas et al. | Dec 1999 | A |
| 6007523 | Mangosong | Dec 1999 | A |
| 6007557 | Ambrisco et al. | Dec 1999 | A |
| 6010517 | Baccaro | Jan 2000 | A |
| 6010522 | Barbut et al. | Jan 2000 | A |
| 6013093 | Nott et al. | Jan 2000 | A |
| 6024754 | Engelson | Feb 2000 | A |
| 6024755 | Addis | Feb 2000 | A |
| 6024756 | Huebsch et al. | Feb 2000 | A |
| 6027520 | Tsugita et al. | Feb 2000 | A |
| 6033420 | Hahnen | Mar 2000 | A |
| 6042598 | Tsugita et al. | Mar 2000 | A |
| 6048331 | Tsugita et al. | Apr 2000 | A |
| 6051014 | Jang | Apr 2000 | A |
| 6051015 | Maahs | Apr 2000 | A |
| 6056720 | Morse | May 2000 | A |
| 6063070 | Eder | May 2000 | A |
| 6068621 | Balceta et al. | May 2000 | A |
| 6074357 | Kaganov et al. | Jun 2000 | A |
| 6076012 | Swanson et al. | Jun 2000 | A |
| 6079414 | Roth | Jun 2000 | A |
| 6080182 | Shaw et al. | Jun 2000 | A |
| 6080183 | Tsugita et al. | Jun 2000 | A |
| 6083239 | Addis | Jul 2000 | A |
| 6096053 | Bates | Aug 2000 | A |
| 6110243 | Wnenchak et al. | Aug 2000 | A |
| 6124523 | Banas et al. | Sep 2000 | A |
| 6132438 | Fleischman et al. | Oct 2000 | A |
| 6135991 | Muni et al. | Oct 2000 | A |
| 6136016 | Barbut et al. | Oct 2000 | A |
| 6139527 | Laufer et al. | Oct 2000 | A |
| 6139573 | Sogard et al. | Oct 2000 | A |
| 6152144 | Lesh et al. | Nov 2000 | A |
| 6156055 | Ravenscroft | Dec 2000 | A |
| 6161543 | Cox et al. | Dec 2000 | A |
| 6171329 | Shaw et al. | Jan 2001 | B1 |
| 6179859 | Bates et al. | Jan 2001 | B1 |
| 6214029 | Thill et al. | Apr 2001 | B1 |
| 6231561 | Frazier et al. | May 2001 | B1 |
| 6231589 | Wessman et al. | May 2001 | B1 |
| 6251122 | Tsukernik | Jun 2001 | B1 |
| 6258115 | Dubrul | Jul 2001 | B1 |
| 6270490 | Hahnen | Aug 2001 | B1 |
| 6277138 | Levinson et al. | Aug 2001 | B1 |
| 6290674 | Roue et al. | Sep 2001 | B1 |
| 6319251 | Tu et al. | Nov 2001 | B1 |
| 6328727 | Frazier et al. | Dec 2001 | B1 |
| 6342062 | Suon et al. | Jan 2002 | B1 |
| 6346116 | Brooks et al. | Feb 2002 | B1 |
| 6364895 | Greenhalgh | Apr 2002 | B1 |
| 6368338 | Konya et al. | Apr 2002 | B1 |
| 6371971 | Tsugita et al. | Apr 2002 | B1 |
| 6375670 | Greenhalgh | Apr 2002 | B1 |
| 6391044 | Yadav et al. | May 2002 | B1 |
| 6402746 | Whayne et al. | Jun 2002 | B1 |
| 6419669 | Frazier et al. | Jul 2002 | B1 |
| 6440152 | Gainor et al. | Aug 2002 | B1 |
| 6443972 | Bosma et al. | Sep 2002 | B1 |
| 6447530 | Ostrovsky et al. | Sep 2002 | B1 |
| 6468291 | Bates et al. | Oct 2002 | B2 |
| 6511496 | Huter et al. | Jan 2003 | B1 |
| 6517573 | Pollock et al. | Feb 2003 | B1 |
| 6547760 | Samson et al. | Apr 2003 | B1 |
| 6551303 | Van Tassel et al. | Apr 2003 | B1 |
| 6551344 | Thill | Apr 2003 | B2 |
| 6558405 | McInnes | May 2003 | B1 |
| 6562058 | Seguin et al. | May 2003 | B2 |
| 6599308 | Amplatz | Jul 2003 | B2 |
| 6652555 | VanTassel et al. | Nov 2003 | B1 |
| 6652556 | VanTassel et al. | Nov 2003 | B1 |
| 6689150 | VanTassel et al. | Feb 2004 | B1 |
| 6730108 | Van Tassel et al. | May 2004 | B2 |
| 6837901 | Rabkin et al. | Jan 2005 | B2 |
| 6855153 | Saadat | Feb 2005 | B2 |
| 6949113 | Van Tassel et al. | Sep 2005 | B2 |
| 6994092 | van der Burg et al. | Feb 2006 | B2 |
| 7011671 | Welch | Mar 2006 | B2 |
| 7044134 | Khairkhahan et al. | May 2006 | B2 |
| 7128073 | van der Burg et al. | Oct 2006 | B1 |
| 8062282 | Kolb | Nov 2011 | B2 |
| 8491623 | Vogel et al. | Jul 2013 | B2 |
| 9314584 | Riley et al. | Apr 2016 | B1 |
| 10758241 | Lashinski et al. | Sep 2020 | B1 |
| 20010034537 | Shaw et al. | Oct 2001 | A1 |
| 20020022860 | Borillo et al. | Feb 2002 | A1 |
| 20020035374 | Borillo et al. | Mar 2002 | A1 |
| 20020062133 | Gilson et al. | May 2002 | A1 |
| 20020082638 | Porter et al. | Jun 2002 | A1 |
| 20020138094 | Borillo et al. | Sep 2002 | A1 |
| 20020138097 | Ostrovsky et al. | Sep 2002 | A1 |
| 20030023266 | Borillo et al. | Jan 2003 | A1 |
| 20030057156 | Peterson et al. | Mar 2003 | A1 |
| 20030181942 | Sutton et al. | Sep 2003 | A1 |
| 20030220667 | van der Burg et al. | Nov 2003 | A1 |
| 20040098031 | van der Burg et al. | May 2004 | A1 |
| 20040215230 | Frazier et al. | Oct 2004 | A1 |
| 20050004652 | van der Burg et al. | Jan 2005 | A1 |
| 20050113861 | Corcoran et al. | May 2005 | A1 |
| 20050203568 | Burg et al. | Sep 2005 | A1 |
| 20070232992 | Kutsko et al. | Oct 2007 | A1 |
| 20080033241 | Peh et al. | Feb 2008 | A1 |
| 20120172731 | Smith | Jul 2012 | A1 |
| 20130110106 | Richardson | May 2013 | A1 |
| 20130165965 | Carlson et al. | Jun 2013 | A1 |
| 20130345574 | Davies et al. | Dec 2013 | A1 |
| 20140018841 | Peiffer et al. | Jan 2014 | A1 |
| 20140039536 | Cully et al. | Feb 2014 | A1 |
| 20140100596 | Rudman et al. | Apr 2014 | A1 |
| 20140180239 | Mittermeyer et al. | Jun 2014 | A1 |
| 20140188157 | Clark | Jul 2014 | A1 |
| 20140323887 | Anderson et al. | Oct 2014 | A1 |
| 20140336612 | Frydlewski et al. | Nov 2014 | A1 |
| 20140364941 | Edmiston et al. | Dec 2014 | A1 |
| 20150119724 | Weber et al. | Apr 2015 | A1 |
| 20150196300 | Tischler et al. | Jul 2015 | A1 |
| 20160106437 | Van Der Burg et al. | Apr 2016 | A1 |
| 20160287259 | Hanson et al. | Oct 2016 | A1 |
| 20160310148 | Allen | Oct 2016 | A1 |
| 20170172722 | Dillard et al. | Jun 2017 | A1 |
| 20180042719 | Chambers | Feb 2018 | A1 |
| 20180338824 | VanTassal et al. | Nov 2018 | A1 |
| 20190223883 | Anderson et al. | Jul 2019 | A1 |
| 20190374229 | Anderson et al. | Dec 2019 | A1 |
| 20200107836 | O'Halloran | Apr 2020 | A1 |
| 20200138446 | Jockenhoevel et al. | May 2020 | A1 |
| 20200383688 | Olson et al. | Dec 2020 | A1 |
| 20210045691 | Zou | Feb 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 106859722 | Jun 2017 | CN |
| 9313712 | Jul 1993 | WO |
| 9640356 | Dec 1996 | WO |
| 9721402 | Jun 1997 | WO |
| 9728749 | Aug 1997 | WO |
| 9802100 | Jan 1998 | WO |
| 9817187 | Apr 1998 | WO |
| 9823322 | Jun 1998 | WO |
| 9827868 | Jul 1998 | WO |
| 9907289 | Feb 1999 | WO |
| 9908607 | Feb 1999 | WO |
| 9930640 | Jun 1999 | WO |
| 9944510 | Sep 1999 | WO |
| 0016705 | Mar 2000 | WO |
| 0027292 | May 2000 | WO |
| 0067669 | Nov 2000 | WO |
| 0115629 | Mar 2001 | WO |
| 0121247 | Mar 2001 | WO |
| 0130266 | May 2001 | WO |
| 0130267 | May 2001 | WO |
| 0130268 | May 2001 | WO |
| 0215793 | Feb 2002 | WO |
| 0224106 | Mar 2002 | WO |
| 03032818 | Apr 2003 | WO |
| 2015164836 | Oct 2015 | WO |
| 2016183495 | Nov 2016 | WO |
| 2018017935 | Jan 2018 | WO |
| 2018187732 | Oct 2018 | WO |
| Entry |
|---|
| International Search Report and Written Opinion dated Mar. 30, 2022 for International Application No. PCT/US2021/064094. |
| PCT Search Report from co-pending Application PCT/US02/33808 dated May 20, 2003. |
| PCT Search Report from PCT/US99/26325 dated Feb. 15, 2000. |
| Cragg et al; “Nonsurgical Placement of Arterial Endoprosthesis: A New Technique Using Nitinol Wire,” Radiology vol. 147, No. 1 pp. 261-263, Apr. 1983. |
| Cragg et al; “A New Percutaneous Vena Cava Filter”, ALJ, 141: 601-604, Sep. 1983. |
| Sugita et al; “Nonsurgical Implantation of a Vascular Ring Prosthesis Using Thermal Shape Memory Ti/Ni Alloy (Nitinol Wire),” Trans. Am. Soc. Artif. Intern. Organs, vol. XXXII, 30-34, 1986. |
| Ruttenberg, Nonsurgical Therapy of Cardiac Disorders, Pediatric Consult, vol. 5, No. 2, pages not numbered, 1986. |
| Rashkind et al; “Nonsurgical Closure of Patent Ductus Arteriosus: Clinical Application of the Rashkind PDA Occluder System,” Circulation 75, No. 3, 583-592-1987. |
| Lock et al; “Transcatheter Umbrella Closure of Congenital Heart Defects,” Circulation, vol. 75, No. 3, 593-599, 1987. |
| Lock et al; “Transcatheter Closure of Artrial Septal Defects,” Circulation, vol. 79, No. 5 1091-1099, May 1989. |
| Wessel et al; “Outpatient Closure of the Patent Ductus Arteriosus,” Circulation, vol. 77, No. 5 1068-1071, 1988. |
| Invitation to Pay Additional Fees dated Feb. 22, 2019 for International Application No. PCT/US2018/066163. |
| Invitation to Pay Additional Fees dated Aug. 19, 2019 for International Application No. PCT/US2019/036063. |
| International Search Report and Written Opinion for Application No. PCT/US2019/030220, 11 pages, dated Aug. 2, 2019. |
| International Search Report and Written Opinion dated Sep. 9, 2019 for International Application No. PCT/US2019/033698. |
| Number | Date | Country | |
|---|---|---|---|
| 20220192677 A1 | Jun 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63127573 | Dec 2020 | US |
